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Abstract
Endometriosis is a chronic gynecological condition that can cause
dysmenorrhea, pelvic pain, and dyspareunia. Standard treatments, 
including both pharmacologic therapy and surgery, can often fail and 
patients still feel endometriosis related pain. Newer pharmacologic 
agents (elagolix) that affect the gonadotropin releasing hormone (GnRH) 
receptors have been developed specifically to treat endometriosis 
associated symptoms. The purpose of this paper was to compare the 
efficacy of these new medications to the already established efficacy of 
oral contraceptive pills and NSAIDs. 
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Endometriosis is a gynecological condition that affects females of 
reproductive age, and 50% of women with infertility. This condition is 
characterized by growth of endometrial-like tissue outside of the uterus, 
and can cause dysmenorrhea, pelvic pain, and dyspareunia. The standard 
first line medications include oral contraceptive pills—which aim to 
suppress ovulation and menses—used in combination with NSAIDs. If 
pharmacological therapy fails and patients still experience pain, surgical 
intervention is often necessary. However, many patients still experience 
pain regardless of these therapies, so it is important to explore other 
treatment options. Newer pharmacologic agents that affect the 
gonadotropin releasing hormone (GnRH) receptors have been developed 
specifically to treat endometriosis associated symptoms. Thus, this paper 
poses the following question: in females with endometriosis [P], are 
medications that affect GnRH receptors [I] more effective at treatment 
of pain [O] than oral contraceptives or NSAIDs [C]?
Introduction
Methods
A literature search was conducted through the Pennsylvania State 
University Libraries and PubMed in November 2019. After this search five 
articles were chosen based on their relevance to the PICO question, year 
of publication, study design, and outcome measurements. The results of 
these articles were then compared. 
Positive results were found for the intervention being looked 
at in each article, however they showed no significant 
difference between GnRH medications and OCPs. The 
blinding, timeline, and follow up were found to be 
“adequate” for the majority of the articles, while potential 
biases were found to be “moderate” for the majority of the 
articles. In order to better compare and evaluate these 
medications, further research should focus on: 
Discussion 
Table 1. Comparison of Study Design
Results 
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In females with endometriosis, are medications that affect GnRH more 
effective at treatment of pain than oral contraceptives or NSAIDs?
The studies looking at GnRH medications had positive results—all 
indicated that they reduce endometriosis related pain. However, one 
study does not show benefit of these medications over OCPs—it 
indicated that both had comparable efficacy in treating endometriosis 
related pain. Another study showed negative long-term health effects of 
these medications. 
The results from these studies as a whole do not seem to support the 
use of GnRH medications over OCPs, and the risks do not seem to 
outweigh the benefits. 
There is not enough evidence to support the use of GnRH medications 
over the traditional therapy of OCPs. For clinical practice this means that 
OCPs may currently remain the best therapy for endometriosis. Despite 
this, the evidence surrounding GnRH medications is promising, and more 
research in this area could further reveal its efficacy and safety. If 
clinicians should choose to prescribe these medications, they should 
weigh the risks and benefits on a case by case basis, since different 
patients can respond differently. Going forward, clinicians should try to 
stay up to date on this ongoing body of research to remain 
knowledgeable of the role of GnRH medications in the treatment of 
endometriosis related pain. 
Conclusion
Table 2. Summary of Results
Of the five studies analyzed in this paper, only one study 
directly compared the use of GnRH medications to oral 
contraceptive pills. Two studies compared GnRH medications 
to placebo, one compared oral contraceptive pills to NSAIDs, 
and one looked at the long-term effects of GnRH 
medications. While the focus of each article was different, all 
evaluated at least one of the following outcomes: 
improvement in dysmenorrhea, non-menstrual pelvic pain, 
or dyspareunia. The results indicate that GnRH medications 
do improve endometriosis related pain, but the benefit over 
OCPs was not statistically significant.







Carr et al S S NS
Taylor et al S S S
Diamond et al S NS S
Grandi at al  S S S
Gallagher et al NS NA NA
Key: S = statistically significant; NS = non-significant; NA = not applicable (the study 
did not measure this value) 
Future 
Research
•Direct comparison of GnRH medications, 
OCPs, and NSAIDS
•Longer study length 
•Less potential for observer bias
